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Sherri L. Christian† and Mark D. Berry*†
Department of Biochemistry, Memorial University of Newfoundland, St. John’s, NL, Canada
Trace amines and their receptors (trace amine-associated receptors; TAARs) are
an emerging pharmacological target for the treatment of human disorders. While
most studies have focused on their therapeutic potential for neurologic and
psychiatric disorders, TAARs are also expressed throughout the periphery, including
prominent expression in human leukocytes. Furthermore, recent independent, unbiased
metabolomic studies have consistently identified one or more TAAR ligands as potential
etiologic factors in inflammatory bowel disease (IBD). The putative role of TAARs in
diseases such as IBD that are associated with hyperactive immune responses has
not, however, previously been systematically addressed. Here, we review the current
state of the knowledge of the effects of TAARs on leukocyte function, in particular in
the context of mucosal epithelial cells that interface with the environment; developing a
model whereby TAARs may be considered as a novel therapeutic target for disorders
associated with dysregulated immune responses to environmental factors. In this
model, we hypothesize that altered trace amine homeostasis results in hyperactivity
of the immune system. Such loss of homeostasis can occur through many different
mechanisms including TAAR polymorphisms and altered trace amine load due to
changes in host synthesis and/or degradative enzymes, diet, or microbial dysbiosis.
The resulting alterations in TAAR functioning can then lead to a loss of homeostasis
of leukocyte chemotaxis, differentiation, and activation, as well as an altered ability of
members of the microbiota to adhere to and penetrate the epithelial cell layers. Such
changes would generate a pro-inflammatory state at mucosal epithelial barrier layers
that can manifest as clinical symptomatology such as that seen in IBD. These alterations
may also have the potential to induce systemic effects, which could possibly contribute
to immunomodulatory disorders in other systems, including neurological diseases.
Keywords: Crohn’s disease, tyramine, phenylethylamine, inflammatory bowel disease, trace amines, leukocytes,
immune system
INTRODUCTION
Since the discovery of trace amine-associated receptors (TAARs) in 2001 (Borowsky et al., 2001;
Bunzow et al., 2001), there has been a gradually growing interest in the therapeutic potential of
this family of receptors. This interest has largely focused on the most well-characterized family
member, TAAR1, and its potential as a novel target for pharmacotherapy of psychiatric disorders,
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in particular schizophrenia (Revel et al., 2013) and drug abuse
(Pei et al., 2016), and more recently metabolic disorders (Raab
et al., 2016). In this article, we will present evidence that leads
us to propose that TAARs also comprise a potential therapeutic
target for disorders associated with an environmentally induced
hyper-reactive immune state. Recent review articles have
thoroughly covered general (Pei et al., 2016) and human (Berry
et al., 2017) TAAR pharmacology to which the reader is referred
for more detailed background information. Here, we will focus
our discussion on recent evidence that supports a role for TAARs
in regulating immune cell functions, and also implicates changes
in endogenous TAAR ligands in the etiology of dysfunctional
immune responses at epithelial cell barrier layers, with a
particular view toward the gastrointestinal tract, which has had
the most focus up until now. From these studies, we will develop
the hypothesis that TAARs are novel therapeutic targets for
environmental hypersensitivity and other immunomodulatory
disorders.
EVOLUTION AND GENETICS OF HUMAN
TAARs
Compared to many other G protein-coupled receptors, TAARs
show a quite pronounced species-dependent diversity due
to a large number of species-specific duplications, deletions,
and pseudogenizations. In mammals, each species’ TAAR
complement clusters together as single exon genes (with
the exception of TAAR2 which contains two exons) on a
single chromosome. Within the nine mammalian TAAR sub-
families, there are two distinct clades comprising TAAR1–4 and
TAAR5–9. TAAR1–4 are evolutionarily the oldest members, with
TAAR1 the oldest and TAAR4 the second oldest (Lindemann
et al., 2005; Eyun et al., 2016), appear to be tuned to the detection
of primary amines (Ferrero et al., 2012), and are under negative
selection pressures (Eyun et al., 2016). By contrast, TAAR5–9
are tuned toward tertiary amines (Ferrero et al., 2012) and
are under strong positive selection pressures (Hussain et al.,
2009; Vallender et al., 2010), with a variety of species-specific
isoforms identified (Eyun et al., 2016). Such positive selection
pressures may indicate an evolutionary role in environmental
adaptation responses, and indeed the TAAR expression profiles of
at least some species may respond to habitat changes (Churcher
et al., 2015; Fatsini et al., 2016). Furthermore, with the notable
exception of TAAR1, TAARs have also now been confirmed as
a new family of receptors involved in olfaction, which respond
to volatile signaling molecules associated with diverse ecological
contexts (Liberles, 2015).
Human TAAR Isoforms
In humans, TAAR genes are located on chromosome 6q23.2
(Borowsky et al., 2001; Bunzow et al., 2001) with six functional
genes (TAAR1, TAAR2, TAAR5, TAAR6, TAAR8, and TAAR9)
and three pseudogenes (TAAR3, TAAR4, and TAAR7) present
(Lindemann et al., 2005). Function-modifying polymorphisms
of TAAR1 (Shi et al., 2016), TAAR2 (Bly, 2005), TAAR6 (Duan
et al., 2004; Pae et al., 2008, 2010; Chang et al., 2015), and
TAAR9 (Vanti et al., 2003; Muller et al., 2010) have been reported.
While such genetic variants have been suggested to have clinical
relevance, reports have rarely been independently validated, and
studies are often confined to rather small sample sizes, making
firm conclusions of the putative clinical relevance difficult.
Endogenous TAAR Ligands
Although only TAAR1 has been officially de-orphanized
(Alexander et al., 2017), a number of endogenous ligands for
individual TAAR isoforms have been identified, many of which
are simply the decarboxylation products of amino acids. Notable
endogenous ligands of individual TAARs are 2-phenylethylamine
(PEA), p-tyramine (TYR), and tryptamine, all of which activate
TAAR1, and probably also TAAR4; trimethylamine (TMA), a
tertiary amine product of the microbial degradation of carnitine
and choline, is a high affinity agonist at TAAR5; and as yet
unidentified TAARs are activated by the diamines putrescine and
cadaverine.
2-PEA and p-TYR
2-Phenylethylamine and p-TYR (Simmler et al., 2016), as well
as a number of other endogenous amines such as tryptamine
(Simmler et al., 2016), 3-iodothyronamine (Scanlan et al., 2004),
and 3-methoxytyramine (Bunzow et al., 2001; Sotnikova et al.,
2010) are selective agonists at human TAAR1. PEA and TYR
are the products of aromatic L-amino acid decarboxylase
(AADC)-mediated decarboxylation of L-phenylalanine
and L-tyrosine, respectively, with degradation occurring
primarily via monoamine oxidase (Figure 1). Subsequent
enzymatic conversion to a variety of other TAAR ligands
such as p-octopamine, N-methylphenylethylamine, and
N-methyltyramine is also possible (Figure 1). While PEA
synthesis is often reported as being neuronal, AADC is also
present in a number of non-neuronal tissues including epithelial
cells of the gastrointestinal tract (Lauweryns and Van Ranst, 1988;
Vieira-Coelho and Soares-da-Silva, 1993) and lungs (Lauweryns
and Van Ranst, 1988; Linnoila et al., 1993). In addition,
L-phenylalanine and L-tyrosine are readily decarboxylated by
commensal prokaryotes (Marcobal et al., 2006; Irsfeld et al.,
2013; Williams et al., 2014) providing an additional pathway
for the production of PEA and TYR in tissues that interface
with the environment. Furthermore, dietary intake provides
a third source of PEA and TYR in the gastrointestinal tract.
Both compounds have long been recognized as being enriched
in commonly ingested foods; with aged cheeses, red wine,
chocolate, and fermented meats particularly well documented
for their enriched levels of PEA and/or TYR (Coutts et al., 1986).
In general, any foods that involve anaerobic fermentation as part
of their production can be expected to contain elevated levels
of one or more trace amines (Toro-Funes et al., 2015; Gardini
et al., 2016; Pessione and Cirrincione, 2016). Indeed, the ability
to detect increased levels of compounds such as TYR and PEA
in microbe-contaminated foods may be one of the evolutionary
driving forces for the appearance of TAARs in the olfactory
epithelium. Seafood also provides a rich source of TYR and
PEA, as well as other putative TAAR ligands (An et al., 2015; Biji
et al., 2016). The potential of such dietary sources to lead to the
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activation of host TAARs, particularly in sensitive individuals,
has only just begun to be recognized by those with research
interests other than TAARs (Ohta et al., 2017). All known
endogenous ligands for TAARs are volatile, and have been
identified in the urine and feces from a number of species. As
such, inhalation of TAAR ligands associated with environmental
sources is an additional source of trace amines in the pulmonary
system.
Once synthesized, ingested, or inhaled, there appears to be no
storage mechanism for either PEA or TYR in mammalian cells.
The half-life for the endogenous pool is less than 30 s (Durden
and Philips, 1980) indicating a very high turn-over rate with
typical tissue concentrations being in the 1–10 ng/g tissue range,
equating to approximately 10–100 nM (Berry, 2004). Release
of TYR and PEA from neuronal preparations is dependent
solely on the total tissue levels (Henry et al., 1988; Dyck, 1989),
consistent with a diffusion-mediated process and a lack of storage
(Juorio et al., 1988). We have confirmed ready diffusion of TYR
across synthetic lipid bilayers (Berry et al., 2013), and in native
membrane preparations this appears to be further enhanced by
the presence of organic cation transporter 2 (OCT2; Slc22A2), a
bidirectional facilitated diffusion transporter which exhibits a Kt
for TYR of '100 nM (Berry et al., 2016). Taken together, these
studies indicate that PEA and TYR readily cross cell membranes,
a situation that means local levels of PEA and TYR exist in a
steady state and are sensitive to fluctuations in synthesis and/or
degradation.
Trimethylamine
During the initial classification of TAARs as receptors involved
in olfaction, TMA was identified as a potent, selective agonist
at human TAAR5 (Liberles and Buck, 2006), a finding that
has subsequently been independently verified (Wallrabenstein
et al., 2013; Zhang et al., 2013). Interestingly, there is no
known mammalian pathway for the production of TMA.
Rather, TMA synthesis appears to be due to the action
of the constitutive microbiota on betaine, carnitine, and
(phosphatidyl)choline (Craciun and Balskus, 2012; Zhu et al.,
2014; Kalnins et al., 2015). As such, TMA represents a good
candidate molecule for involvement in microbe-host signaling
cascades. Moreover, elevated TMA levels have been found to
result from dysbiosis in the intestines, vagina, and oral cavity
(Fennema et al., 2016; Zhang and Davies, 2016). Degradation
of TMA occurs almost exclusively in the liver through the
action of flavin monooxygenase 3 (FMO3) (Fennema et al.,
2016). This raises interesting pharmacokinetic questions since
the site of degradation is relatively distant from the site of
production, thus raising the possibility of tonic activation of
any TAAR5 that is present between the two sites. Indeed,
TMA has been identified as a constituent of numerous body
fluids (Mitchell and Smith, 2016). This possibility is further
strengthened when considering that the Km of FMO3 for TMA
is 28 µM (Lang et al., 1998), 100-fold in excess of the EC50
of TMA at human TAAR5 (Berry et al., 2017). Outside of the
mammalian body, TMA production is associated with bacterial
degradation of meat products, in particular fish (Horowitz et al.,
2014).
Cadaverine, Putrescine, and Other Polyamines
In experimental animals, the pan knockout of the TAAR2–
TAAR9 cluster eliminates behavioral responses to the presence
of cadaverine and putrescine (Dewan et al., 2013). Furthermore,
a number of teleost-specific TAAR isoforms are also activated by
cadaverine (Hussain et al., 2013) and other diamines (Li et al.,
2015). The relevance of these observations to human physiology
is supported by the recent identification of a putative diamine-
binding site in human TAAR6 and TAAR8 (Li et al., 2015;
Izquierdo et al., 2018), which has been predicted via in silico
analysis to bind cadaverine and putrescine (Izquierdo et al.,
2018).
Both putrescine and cadaverine are produced by the
decarboxylation of precursor L-amino acids, ornithine via
ornithine decarboxylase in the case of putrescine, and lysine via
lysine decarboxylase in the case of cadaverine (Miller-Fleming
et al., 2015; Pegg, 2016). Like other TAAR ligands, both are also
produced by microbial action on proteinaceous materials, and as
such are associated with decaying flesh. Indeed, putrescine and
cadaverine are often credited with being the “smell of death.”
Tissue and Cellular Distribution of TAARs
One of the factors that has hampered the advancement of TAAR
pharmacology has been a general lack of suitable reagents to
probe the individual isoforms (see Berry et al., 2017 for details).
Basal expression levels of TAARs are generally very low, and
only TAAR1 has been studied in detail. Indeed, TAAR1 is the
only isoform for which a well-validated anti-human antibody
has been described (Raab et al., 2016). With respect to the
TAAR family in general, the most well-replicated finding has
been the presence of all TAAR isoforms except TAAR1 in the
olfactory epithelium, including in humans (Liberles and Buck,
2006; Hashiguchi and Nishida, 2007; Gliem et al., 2009; Horowitz
et al., 2014; Kanageswaran et al., 2015; Syed et al., 2015). In
these olfactory systems, individual isoforms have been shown to
respond to a variety of volatile amines associated with distinct
ecological cues (Ferrero et al., 2011; Dewan et al., 2013; Li et al.,
2013; Zhang et al., 2013; Liberles, 2015; Santos et al., 2016)
including predator presence, spoiled food, and conspecifics of
the opposite gender. In addition, individual TAARs are also
expressed throughout the body, including both central nervous
and peripheral organ systems (Berry et al., 2017).
TAAR1
While TAAR1 is well established as being expressed throughout
the brain of experimental animals, primarily associated with the
major monoaminergic (in particular, although not exclusively,
dopaminergic) nuclei and projection areas, few studies have
attempted to confirm such findings in humans (Borowsky
et al., 2001; Lindemann et al., 2005). It is likely that a similar
distribution is present in humans, a situation supported by
the observation of a normalization of functional magnetic
resonance imaging (fMRI) in various brain regions, in particular
those associated with the dopaminergic reward circuitry, by a
mixed 5-HT1A/TAAR1 compound in patients with schizophrenia
(Nazimek et al., 2016). Similar modifications of brain activity in
response to a highly selective TAAR1 agonist had previously been
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FIGURE 1 | Schematic representation of trace amine synthetic and degradative pathways. 2-phenylethylamine and p-tyramine are primarily synthesized by
decarboxylation of precursor amino acids via the enzyme aromatic L-amino acid decarboxylase. Depending on the cell type, L-phenylalanine can be converted into
L-tyrosine via either tyrosine hydroxylase or a dedicated phenylalanine hydroxylase. Degradation of 2-phenylethylamine and p-tyramine is primarily via monoamine
oxidase, 2-phenylethylamine being a highly selective substrate for the B isoform, whereas p-tyramine is a mixed monoamine oxidase-A and -B substrate. Both
2-phenylethylamine and p-tyramine can also be converted to a variety of other compounds that are also agonists at one or more TAAR. MAO, monoamine oxidase.
reported using pharmacological MRI in rodent models (Revel
et al., 2013). Expression of TAAR1 has also been reported to be
present in the spinal cord of multiple species including humans
(Borowsky et al., 2001; Lindemann et al., 2008; Gozal et al., 2014),
as well as in human astrocytes (Cisneros and Ghorpade, 2014).
TAAR1 expression is also present in a number of nutrient
sensing organs in humans, where it appears to regulate hormone
secretion in response to nutrients (Adriaenssens et al., 2015;
Raab et al., 2016). Specifically, TAAR1 has been confirmed
to be present in pancreatic β-cells (Revel et al., 2013; Raab
et al., 2016), D cells of the stomach (Adriaenssens et al., 2015;
Raab et al., 2016), and enterochromaffin mucosal cells of the
intestines (Kidd et al., 2008; Raab et al., 2016). Expression in
human leukocytes (D’Andrea et al., 2003), including peripheral
mononuclear (PMN) cells (Nelson et al., 2007), B lymphocytes
(Wasik et al., 2012; Babusyte et al., 2013), monocytes (Babusyte
et al., 2013), polymorphonuclear leukocytes (Babusyte et al.,
2013), NK cells (Babusyte et al., 2013), and T lymphocytes
(Babusyte et al., 2013; Sriram et al., 2016), has also been
established (Table 1). Furthermore, methamphetamine-mediated
stimulation of T lymphocytes has been reported to increase
TAAR1 expression levels (Sriram et al., 2016). Given that
methamphetamine itself is a TAAR1 agonist (Bunzow et al.,
2001; Simmler et al., 2016), this raises the possibility of a
positive feedback, amplification loop for TAAR1 signaling in T
lymphocytes. Such a positive feedback loop has recently been
described in response to the highly selective TAAR1 agonist
RO5203648 in placental cells (Stavrou et al., 2018).
Notably, the available evidence indicates that TAAR1 resides
primarily intracellularly in all tissues and cell types studied
(Lindemann et al., 2005; Barak et al., 2008; Pei et al., 2016; Raab
et al., 2016), only translocating to the plasma membrane
following agonist-induced receptor heterodimerization
(Espinoza et al., 2011, 2015; Harmeier et al., 2015). Therefore, the
ability of PEA and TYR to readily cross cell membranes either by
diffusion (Berry et al., 2013), OCT2-mediated transport (Berry
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TABLE 1 | TAAR expression in human leukocyte populations.
Receptor
isoform
Immune cell type Transcript or protein
TAAR1 Unspecified
leukocytes
mRNA (D’Andrea et al., 2003)
Peripheral
mononuclear cells
mRNA (Nelson et al., 2007)
B cells mRNA and protein (Babusyte et al.,
2013; Sriram et al., 2016)
Monocytes mRNA (Babusyte et al., 2013)
PML mRNA and protein (Babusyte et al.,
2013)
NK cells mRNA (Babusyte et al., 2013)
T cells mRNA and protein (Babusyte et al.,
2013; Sriram et al., 2016)
TAAR2 Peripheral
mononuclear cells
mRNA (Nelson et al., 2007)
B cells mRNA (Nelson et al., 2007;
Babusyte et al., 2013)
Monocytes mRNA (Babusyte et al., 2013)
PML mRNA and protein (Babusyte et al.,
2013)
NK cells mRNA (Babusyte et al., 2013)
T cells mRNA (Babusyte et al., 2013)
TAAR5 Not present (Nelson
et al., 2007)
B cells mRNA (Babusyte et al., 2013)
Monocytes mRNA (Babusyte et al., 2013)
PML mRNA (Babusyte et al., 2013)
NK cells mRNA (Babusyte et al., 2013)
T cells mRNA (Babusyte et al., 2013)
TAAR6 Unspecified
leukocytes
mRNA (D’Andrea et al., 2003)
B cells mRNA (Babusyte et al., 2013)
Monocytes mRNA (Babusyte et al., 2013)
PML mRNA (Babusyte et al., 2013)
NK cells mRNA (Babusyte et al., 2013)
T cells mRNA (Babusyte et al., 2013)
TAAR8 Unspecified
leukocytes
mRNA (D’Andrea et al., 2003)
Not present
(Babusyte et al.,
2013)
TAAR9 Unspecified
leukocytes
mRNA (D’Andrea et al., 2003)
B cells mRNA (Babusyte et al., 2013)
Monocytes mRNA (Babusyte et al., 2013)
PML mRNA (Babusyte et al., 2013)
NK cells mRNA (Babusyte et al., 2013)
T cells mRNA (Babusyte et al., 2013)
et al., 2016), or via other as yet unidentified transporters, is a
critical first step in TAAR1 signaling cascades.
TAAR2
TAAR2 is a little unusual, being the only family member with
a gene containing more than one exon (Lindemann et al., 2005).
Very little is known, however, about its distribution. In human
leukocytes, there is some evidence that TAAR2 expression
may mirror that of TAAR1, with TAAR2 mRNA reported
in B lymphocytes, monocytes, NK cells, and T lymphocytes
(Nelson et al., 2007; Babusyte et al., 2013), and both mRNA
and protein reported in granulocytes (Babusyte et al., 2013).
The co-localization of TAAR1 and TAAR2 may be functionally
important, with heterodimerization between the two having
possible consequences to TAAR1 signaling (Babusyte et al., 2013).
In laboratory rodents, TAAR2 mRNA has also been reported in
duodenal mucosal cells (Ito et al., 2009), heart (Chiellini et al.,
2007), and testis (Chiellini et al., 2012).
TAAR5
Although there is a known ligand (TMA) identified that
is well established to be present in humans, very few
studies have investigated the expression profile of TAAR5.
A potential preferential expression in human B lymphocytes has
been suggested, with low level expression in other leukocyte
populations (Babusyte et al., 2013). In rodents, TAAR5 mRNA is
expressed in brain, with a distribution partially overlapping that
of TAAR1 (Dinter et al., 2015). Spinal cord (Gozal et al., 2014) and
testis (Chiellini et al., 2012) expression has also been suggested.
TAAR6
In human brain, TAAR6 transcript levels may surpass those of
TAAR1 (Duan et al., 2004), and also be primarily localized to
known monoaminergic projection pathways including amygdala
(Borowsky et al., 2001; Duan et al., 2004), basal ganglia
(Duan et al., 2004), frontal cortex (Duan et al., 2004),
hippocampus (Borowsky et al., 2001; Duan et al., 2004),
and substantia nigra (Duan et al., 2004). Outside of the
brain, TAAR6 transcripts have also been reported in kidney
(Borowsky et al., 2001), and leukocytes (D’Andrea et al., 2003;
Babusyte et al., 2013). Although present in rat spinal cord (Gozal
et al., 2014), no transcripts were found in human (Duan et al.,
2004).
TAAR8
Astroglial TAAR8 transcripts have been reported to be
increased following activation by lipopolysaccharide treatment
(D’Andrea et al., 2012). Elsewhere in the human brain,
TAAR8 mRNA was reported to be present in the amygdala
(Borowsky et al., 2001). D’Andrea et al. (2003) also reported
TAAR8 transcripts in leukocytes, although this was not
confirmed by others (Babusyte et al., 2013). Whether
lipopolysaccharide activation of leukocytes increases TAAR8
levels as observed in astrocytes is unknown. Expression of
TAAR8 in the kidney has also been suggested (Borowsky et al.,
2001).
TAAR9
All leukocyte populations studied have been reported to express
TAAR9 (D’Andrea et al., 2003; Babusyte et al., 2013), with human
expression also suggested in the spleen (Regard et al., 2008),
pituitary gland (Vanti et al., 2003), and skeletal muscle (Vanti
et al., 2003).
Frontiers in Pharmacology | www.frontiersin.org 5 July 2018 | Volume 9 | Article 680
fphar-09-00680 June 28, 2018 Time: 17:56 # 6
Christian and Berry TAARs in Immune System Disorders
TAARs AND THE IMMUNE SYSTEM
Overall, the evidence described above indicates that multiple
TAARs are expressed in the immune system, in particular in
various populations of leukocytes (Table 1), and that in at
least some cases, this is regulated in response to leukocyte
activation. This raises the possibility that TAARs and their ligands
may comprise a hitherto unsuspected target for modulation of
immune function. Furthermore, given the ready production of
such ligands by members of the constitutive microbiota, a role
for TAARs in microbiota-immune system signaling should be
considered. In the following sections, we will review the current
state of the knowledge of the effects of TAARs on leukocyte
function, developing a model whereby TAARs are considered as
potential therapeutically relevant targets in disorders associated
with dysregulated immune responses to environmental factors.
In particular growing evidence indicates TAARs may be attractive
novel molecular targets in inflammatory bowel disease (IBD).
TAARs Regulation of Leukocyte Function
As described above, TAARs are differentially expressed between
various leukocyte populations in humans. Notably, both TAAR1
and TAAR2 expression are increased following leukocyte
activation (Nelson et al., 2007; Wasik et al., 2012). The
endogenous TAAR1 ligands PEA and TYR are chemotactic
for PMN (Babusyte et al., 2013), and can be released from
activated platelets (D’Andrea et al., 2003). It is not known if
TAAR1 ligands are chemotactic for other leukocyte populations
and this is an area for future study. This chemotactic response
is dependent on the expression of both TAAR1 and TAAR2,
possibly due to agonist-induced heterodimerization (Babusyte
et al., 2013), similar to that also reported between TAAR1 and D2-
like dopamine receptors (D2R) (Espinoza et al., 2015; Harmeier
et al., 2015).
Activation of leukocyte TAAR1 may also regulate T helper
(Th) cell differentiation, directing this away from the Th1
phenotype and toward the Th2 phenotype. Supporting this,
a TAAR1-dependent increase in interleukin (IL)-4 secretion,
decrease in IL-2 secretion, and decrease in expression of secreted
phosphoprotein 1 have been reported (Babusyte et al., 2013).
Promotion of the Th2 phenotype would be expected to lead to
increased activation of B lymphocytes, and TAAR1 agonists do
increase B cell secretion of immunoglobulin E (IgE) (Babusyte
et al., 2013). TAAR1-mediated B lymphocyte apoptosis has also
been reported (Wasik et al., 2012). Importantly, all of the above
effects of TAAR1 agonists occur with low nanomolar EC50 values,
well within the range of endogenous TA plasma levels (D’Andrea
et al., 2003). In healthy individuals, PEA and TYR levels are
tightly controlled. As previously described the endogenous pool
exists in a steady state, with no storage and a half-life of less
than 30 s (Durden and Philips, 1980). As such, it is possible
that alterations in TAAR1 signaling can occur simply due to
fluctuations in PEA and/or TYR levels, and such altered signaling
could affect homeostatic immune responses.
In recent years, it has become increasingly apparent that
leukocyte populations are also regulated by receptors commonly
associated with neurotransmission (Pacheco et al., 2014). In
particular, dopamine and its receptors have been shown to
be present in various populations including B lymphocytes,
dendritic cells, neutrophils, NK cells, and T lymphocytes
(Pacheco et al., 2014), and to play a role in signaling between
immune cells (Pacheco et al., 2014; Papa et al., 2017). Activation
of individual dopamine receptors has been shown to be involved
in both B lymphocyte (Papa et al., 2017) and T lymphocyte
activation (Pacheco et al., 2014), T lymphocyte cytokine secretion
and migration (Pacheco et al., 2014), and dependent on the
dopamine receptor sub-type activated promotion of Th1, Th2,
or Th17 differentiation (Pacheco et al., 2014). Since TAAR1 has
been established as an endogenous modulator of D2R, TAAR-
mediated regulation of dopaminergic signaling within immune
cells may also occur, and is perhaps likely. In particular, TAAR1
appears to function as an endogenous rheostat, maintaining
homeostasis of dopaminergic systems (Bradaia et al., 2009;
Revel et al., 2013) by selectively heterodimerizing with D2R
(Espinoza et al., 2011, 2015; Salahpour et al., 2012; Harmeier
et al., 2015). In the central nervous system, this TAAR1 agonist-
induced heterodimerization causes biased signaling involving
the G protein-independent β-arrestin cascade (Espinoza et al.,
2015; Harmeier et al., 2015). Intriguingly, β-arrestin isoforms
have been implicated in autoimmune disorders due to regulation
of both innate and adaptive immune system functions,
including chemotaxis (Jiang et al., 2013), gating cytokine
receptor responsitivity (Gurevich and Gurevich, 2014), Th cell
differentiation (Jiang et al., 2013), epithelial cell barrier functions
(Jiang et al., 2013), and inflammation-induced epithelial cell
apoptosis (Zeng et al., 2015). Therefore, the potential of TAAR1
to regulate D2R signaling via the β-arrestin cascade in leukocytes
warrants parallel systematic investigation alongside the effects of
TAAR1 agonists alone.
TAARs and the Major Histocompatibility
Complex
The major histocompatibility complex (MHC) is a critical
mediator of T lymphocyte activation. Degradation and
presentation of antigens on either class I or class II MHC
by antigen-presenting cells, such as dendritic cells or
macrophages, is essential for activation of CD8+ and CD4+ T
cells, respectively. Interaction of CD8+ T lymphocytes with the
peptide–MHC-I complex, along with the involvement of Th cells,
causes these cells to differentiate into cytotoxic T lymphocytes
(CTL) that can induce the lysis of infected or altered cells.
Interaction of CD4+ Th cells with the peptide–MHC-II complex
induces their activation. In addition, the context provided by
cytokines in the extracellular environment following release
from damaged, infected, or otherwise altered cells present in the
microenvironment further influences the specific differentiation
of CD4+ T cells into the various Th subsets including Th1, Th2,
Th17, and Treg. Intriguingly, TAARs were recently implicated
in the recognition of class I MHC, at least in the context of
MHC-mediated mate selection (Santos et al., 2016). Here, the
TAAR3 genotype was shown to play a role in female selection
of MHC-diverse males by the greater sac-winged bat. While the
context of this detection is not immune cell responsitivity, and
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TAAR3 is a pseudogene in humans, this does indicate that the
possibility of TAARs involvement in MHC-mediated responses
within leukocytes should be considered, and warrants further
study.
TAARs and Their Ligands in IBD
Inflammatory bowel disease comprises a group of chronic
inflammatory disorders, where Crohn’s disease (CD) and
ulcerative colitis (UC) are the two major forms. The etiology
of IBD involves complex multifactorial components including
genetic, immunologic, and environmental influences (Kostic
et al., 2014; Lane et al., 2017; Zhang M. et al., 2017) that
remain to be fully elucidated. Key components of the immune
response in IBD include increased leukocyte recruitment to the
gastrointestinal mucosa (Vitale et al., 2017) involving both innate
and adaptive immune systems, and loss of homeostatic control of
Th cell differentiation into Th1 (Frank et al., 2007; Pacheco et al.,
2014; Zhang M. et al., 2017), Th17 (Lee and Mazmanian, 2010;
Pacheco et al., 2014; Zhang M. et al., 2017), and Treg (Pacheco
et al., 2014; Zhang M. et al., 2017) phenotypes. Normalization
of epithelial cell–immune system communication (Jostins et al.,
2012; Martini et al., 2017) and identification of molecules that
mediate leukocyte chemotaxis (Thomas and Baumgart, 2012;
Bamias et al., 2013) are regarded as promising therapeutic
targets. As described above, TAAR1-mediated signaling, either
direct or through modulation of D2R, may regulate all these
responses. Furthermore, microbial production of trace amines is
also implicated in the ability of microbes to adhere to epithelial
cells, and in subsequent internalization of microbes and epithelial
cell cytokine production (Fernandez de Palencia et al., 2011;
Luqman et al., 2018).
Among the most prominent environmental influences in
IBD are a decreased complexity of the constitutive microbiota
(Frank et al., 2007; Kostic et al., 2014; Lane et al., 2017)
and various dietary factors (Kostic et al., 2014; Lewis et al.,
2015; Lane et al., 2017; Sigall-Boneh et al., 2017; Zhang M.
et al., 2017). The presence of TAARs in almost all leukocyte
populations, and the availability of their ligands from intestinal
epithelial cells, the microbiota, and food, indicates that the trace
aminergic system is conveniently positioned at the interface of
genetics, leukocyte chemotaxis and activation, microbiota, and
diet (Figure 2). The putative involvement of TAARs in IBD,
however, has not previously been systematically addressed or
formally hypothesized.
Changes in trace amine metabolism have recently been
correlated to both IBD disease status (Wilson et al., 2015; Santoru
et al., 2017) and the decreased microbiota complexity that is a
defining characteristic of IBD (Santoru et al., 2017). Unbiased
metabolomic screens have directly implicated dysregulation of
known TAAR ligands in the pathology of IBD, although the
presence of high affinity receptors for these compounds has
been overlooked. Most notably, PEA has been reported to be
increased in fecal samples from CD patients, and to be one of
the metabolites that allows discrimination of CD from healthy
patient populations (Jacobs et al., 2016; Santoru et al., 2017).
Such results are also consistent with previous studies identifying
altered tyrosine and phenylalanine metabolism as a factor for
discriminating IBD from healthy populations (Burczynski et al.,
2006; Jansson et al., 2009). Putrescine and cadaverine have also
been identified as selectively elevated in CD patients (Santoru
et al., 2017) consistent with previous reports of altered lysine
metabolism (Marchesi et al., 2007). Likewise, in UC patients,
significant elevations in TYR and cadaverine have been reported
(Santoru et al., 2017). Furthermore, elevated levels of fecal
TMA have been reported in IBD (Marchesi et al., 2007), along
with both elevations and reductions of its primary metabolite
trimethylamine-N-oxide (TMAO) (Wilson et al., 2015; Santoru
et al., 2017).
Despite these identified changes in TAAR ligands, there
appears to be only a single study that has identified possible roles
of TAARs in IBD (Taquet et al., 2012). Here, in an unbiased
microarray screen, TAAR2, TAAR5, and TAAR9 were found
to be among the most highly upregulated genes in biopsies
from inflamed regions of CD patients, and contributed to
the separation of CD patients from those with irritable bowel
syndrome (Taquet et al., 2012). Although neither PEA nor TYR
are agonists at TAAR2, the aforementioned heterodimerization
of TAAR2 with TAAR1 could provide a link between the altered
TYR and PEA metabolomic profiles and TAAR2 over-expression,
both of which allow discrimination of IBD populations. It is
also worth noting that activity-modifying polymorphisms of D2R
have been implicated in CD (Magro et al., 2006). As such,
given the well-documented role of TAAR1 in normalizing D2R
signaling, even in the absence of de facto changes in TAAR1
or its endogenous ligands, it may still be a viable target for
pharmacotherapy. Importantly in this aspect, TAAR1-directed
therapeutics have been confirmed in phase I clinical trials to be
generally safe (Fowler et al., 2015).
A TAAR-centric Hypothesis of IBD
Based on the above evidence, we hypothesize that altered trace
amine homeostasis can result in hyperactivity of the immune
system which clinically can manifest as IBD. Such loss of
homeostasis can occur through many different mechanisms. For
example: polymorphisms of one or more TAAR resulting in
altered leukocyte homeostasis; changes to trace amine levels
as a result of altered synthesis and/or degradation; or altered
trace amine load due to microbial action, diet, or altered trace
amine transport properties. Such altered levels can then result
in changes in chemotaxis and/or activation of leukocytes, and/or
TA-induced changes in the ability of members of the microbiota
to adhere to and penetrate the epithelial cell layer. Furthermore,
in situations with primary dysbiosis, alterations of trace amine
production by the constitutive microbiota could easily manifest,
which may lead to loss of homeostasis of leukocyte chemotaxis
and activation and/or increased sensitivity to foods containing
trace amines or their precursors.
A Role for TAARs in Immune Disorders of
Other Organ Systems
In addition to a putative role for TAARs in gastrointestinal
immune system dysfunction, coordination between the host
immune system, epithelial cells, and the constitutive microbiota
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FIGURE 2 | Schematic diagram of hypothetical interactions between trace amines (TA) and the mucosal epithelial layer immune system. TA levels can increase due
to an increased activity of aromatic L-amino acid decarboxylase (AADC) in intestinal epithelial cells, or by exogenous sources including food, microbial activity,
decaying animals, or in secretions such as urine, sweat, or breath. In humans, trimethylaminuria [fish (mal)odor syndrome] increases the secretion of TMA. TA cross
lipid bilayers, including both the apical and basolateral surfaces of the intestinal epithelium, by a combination of simple diffusion and transporter-mediated facilitated
diffusion. The overarching hypothesis illustrated is that pathological accumulation of TA in the basolateral compartment may (a) recruit immune cells to the area
and/or (b) induce the differentiation of T cells to promote inflammation and subsequent damage to the epithelium. Dashed orange lines indicate movement of TA,
dashed blue lines indicate movement of immune cells, and the balance beams indicate a potential TA-induced shift in the balance of T helper cell phenotypes. MALT,
mucosal-associated lymphoid tissue; DC, dendritic cell.
needs to occur and be tightly controlled in many other situations.
In particular, a similar complex trilateral communication
network is present in the pulmonary and urogenital systems, and
a similar role for the trace aminergic system could occur in each
of these. Furthermore, a role for dysregulated immune systems
in neurologic and psychiatric disorders is becoming increasingly
recognized. With few studies available, firm links in each of these
systems requires a great deal more foundational work.
The Pulmonary System
In recent years, there has been a growing appreciation of possible
links between pulmonary hypersensitivity disorders such as
environmentally induced asthma, and dysbiosis (Dickson and
Huffnagle, 2015; Hauptmann and Schaible, 2016), including
gastrointestinal dysbiosis (Samuelson et al., 2015; Zhang I. et al.,
2017). We are unaware of any studies directly implicating an
altered trace amine metabolome with lung inflammation at
this point in time, but the fact that all known endogenous
TAAR ligands are highly volatile and present in a wide
range of environmental contexts including food and animal
urine and feces, while their receptors appear to play a role
in regulating leukocyte chemotaxis and activation, suggests
a putative link that warrants consideration. It is also worth
noting that polymorphism of TAAR6 has been linked to
corticosterone responsiveness in asthma patients (Chang et al.,
2015). Corticosterone is not known to be a ligand for any
TAAR, suggesting that TAAR6 may be contributing in an indirect
manner.
The Urogenital Tract
Trimethylamine is sexually dimorphic in mice (Gavaghan McKee
et al., 2006), and urinary levels are also reported to be
increased in humans during menstruation (Mitchell and Smith,
2010) possibly due to a sex hormone-induced regulation of its
degradation (Coecke et al., 1998; Shimizu et al., 2007). The
socially stigmatizing odor associated with vaginal dysbiosis is
largely a function of increased TMA levels (Fennema et al.,
2016; Zhang and Davies, 2016). The production of putrescine,
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cadaverine, and TYR have been identified as important virulence
factors in the progression of the dysbiotic environment (Nelson
et al., 2015) and may underlie the increased incidence of bacterial
vaginosis among smokers (Nelson et al., 2018).
The Nervous System
An inflammatory component to, at least, some neurological
disorders is now recognized, and trace amines are synthesized
in neurons, and then immediately released to the extra-neuronal
environment by diffusion mediated events. Such released trace
amines may recruit and activate leukocytes if the homeostatic
equilibrium between synthesis and degradation is lost. While this
is merely theoretical at this time, polymorphism of TAAR1 has
been linked to fibromyalgia sensitivity (Smith et al., 2012), and
fibromyalgia may involve an immune system component.
The central nervous system in IBD
Estimates suggest that upward of 33% of IBD patients report
coincidence of non-gastrointestinal symptoms (Casella et al.,
2014; Dolapcioglu and Dolapcioglu, 2015), and such symptoms
may even precede gastrointestinal symptomatology. While
neuropsychiatric complications are rare, IBD patients do show
an increased risk of cerebrovascular disorders such as stroke
(Dolapcioglu and Dolapcioglu, 2015; Nemati et al., 2017). IBD
is also associated with upto a five-fold increase in demyelinating
disorders such as multiple sclerosis that is independent of
immunosuppressant therapy, and which may be related to a
generalized loss of T lymphocyte homeostasis (Casella et al.,
2014; Dolapcioglu and Dolapcioglu, 2015). Even though the
role of TAARs have not been investigated with respect to
demyelination, TAARs may be a future novel target for control of
neuroinflammation given the increasing evidence for a putative
role in regulating immune cell function and TAARs expression
throughout the brain.
Inflammation in central nervous system disorders
There is an increasing interest in the “gut–brain axis,” with
signals originating in the gastrointestinal tract, including from
the constitutive microbiota, now accepted as regulating central
nervous system function (Fung et al., 2017; Tremlett et al.,
2017). Likewise, the association of low-grade inflammation with
both increased risk of neuropsychiatric disorders and poor
treatment outcomes is increasingly recognized (Osimo et al.,
2018). Such inflammation can be associated with both the central
and peripheral nervous systems and non-neural tissues such as
epithelial cells (Chrysohoou et al., 2018; Nguyen et al., 2018),
and has been identified as a novel therapeutic target (Osimo
et al., 2018). Schizophrenia and bipolar disorder have both
been reported to be associated with an increased prevalence of
gastrointestinal disturbances, including increased inflammation
and a dysfunctional epithelial barrier layer (Nguyen et al., 2018).
Interestingly, a decrease in the constitutive microbiota diversity
may also be associated with psychiatric disorders (Nguyen et al.,
2018).
TAAR1 ligands are already in active development as
treatments for neuropsychiatric disorders (Berry et al., 2017), and
their potential to also modulate hyperactive immune function
could offer an additional benefit. Of particular note is the
spectrum of syndromes associated with chromosome 22q11.2
deletion that includes altered T lymphocyte differentiation
resulting in hyper-reactive responses to environmental stimuli,
and a marked increased risk of schizophrenia (Vergaelen
et al., 2018). One of the genes located to 22q11.2 is
catechol-O-methyltransferase, which catalyzes the conversion
of dopamine and norepinephrine to 3-methoxytyramine and
normetanephrine, both of which are potent TAAR1 agonists. As
such chromosome 22q11.2 deletion likely leads to a deficit in
basal TAAR1 signaling.
The role of inflammation and the constitutive microbiota in
neuropsychiatric indications is an emerging area. One specific
aspect that is unresolved is whether neuroinflammation results
from infiltration of peripheral leukocytes in to the central nervous
system due to a dysfunctional blood–brain barrier, activation of
the central immune cells such as microglia, or a combination of
both. With highly selective TAAR ligands becoming established
as a way to normalize central neuronal function, the putative
ability of the same compounds to normalize factors that regulate
inflammatory effects would be a considerable advantage over
existing therapeutics. As described in preceding sections, there
is growing evidence that TAARs also play a role in regulating
endothelial cell barrier functions and inflammatory responses
in the gastrointestinal system, and possibly also in the placenta
(Stavrou et al., 2018). Whether such effects also occur within
the central nervous system is a key area for future systematic
investigation. As far as we are aware, the TAAR expression profile
of microglia and endothelial cells of the blood–brain barrier have
not yet been examined.
CONCLUDING STATEMENTS
The trace aminergic system is an emerging target for
pharmacotherapy that is garnering increasing interest. We
propose that in addition to neurological/psychiatric and
metabolic disorders, there is increasing evidence to support a
putative role in environmental hypersensitivity immune system
disorders, in particular IBD, and that a systematic investigation
of the role of TAARs and their ligands in leukocyte homeostasis
is warranted. We believe that such a putative role has an
evolutionary basis. TAAR1, while evolutionarily the oldest family
member, is the only isoform that is not involved in olfaction. This
suggests that either this function has been lost in all species from
the cartilaginous fish upward, or that co-opting TAARs to the
olfactory epithelium following a gene duplication event offered
an evolutionary advantage. Given that TAAR1 is under strong
negative selection pressures, and that the second oldest family
member, TAAR4, shares ligand selectivity with TAAR1, we
believe this latter option is the most likely. The ability to detect
compounds in the environment that can also trigger immune
responses, and where that detection induces an innate avoidance
response (as is known to occur), would offer a considerable
advantage in protecting the organism from ingesting microbial
contaminated foods that could be potentially injurious or even
fatal. The fact that these compounds are also excreted in urine
and feces due to intestinal microbiota metabolism of ingested
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meat, offers an additional advantage of triggering avoidance of
areas associated with potential predators. It is also interesting
to note that many aquatic species show an innate avoidance
response to parasites and parasite-infected conspecifics, a
response that is almost indistinguishable from their avoidance of
predators. The chemical basis of this response is unknown, and
TAARs could represent a new possibility for the molecular basis
of such responses.
In conclusion, there is growing evidence that the trace
aminergic system plays a role in the complex tripartite
communication web between the epithelial cells that form a
barrier between the host and the environment, host immune
cells, and the constitutive microbiota, and that loss of trace
amine homeostasis can be associated with immune system hyper-
reactivity toward environmental cues.
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